Short answer
LB PHARMACEUTICALS INC (LBRX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$14M
- EPS (diluted)
- −$6.26
Source: XBRL data from the LB PHARMACEUTICALS INC (LBRX) Q3 2025 10-Q on SEC EDGAR. USD.
LB PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New or changed risk not identifiable; provided excerpt contains no 10-K comparison or explicit newly added factor
- Financial risk: $13.7 million nine-month net loss and $118.1 million accumulated deficit as of September 30, 2025
- Liquidity risk: $314.5 million cash and equivalents expected to fund operations for at least twelve months
- Regulatory risk: FDA may require additional preclinical studies or protocol amendments before future clinical-trial initiation
- Operational risk: Subjective PANSS assessments and elevated placebo effects could undermine LB-102 schizophrenia-trial outcomes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LB PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.